Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
The Miriam Hospital receives Primary Stroke Center certification for fifth consecutive year

The Miriam Hospital receives Primary Stroke Center certification for fifth consecutive year

The Miriam Hospital has for the fifth time been designated by the Joint Commission as a Primary Stroke Center. [More]
AANS, ASTRO partner to launch national registry for SRS treatments

AANS, ASTRO partner to launch national registry for SRS treatments

The American Association of Neurological Surgeons and the American Society for Radiation Oncology are partnering to launch and support a national registry for stereotactic radiosurgery (SRS) treatments. [More]
Cancer-fighting cocktail shows promising results for advanced cervical cancer

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds. [More]
Early-stage Hodgkin's disease patients who receive radiation therapy have better survival rate

Early-stage Hodgkin's disease patients who receive radiation therapy have better survival rate

Patients with stage I and II Hodgkin's Disease who receive radiation therapy (RT) have a higher 10-year survival rate -- 84 percent compared to 76 percent - than those who do not, according to a study presented by researchers at Icahn School of Medicine at Mount Sinai at the American Society for Radiation Oncology's (ASTRO's) 56th Annual Meeting today. [More]
Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. [More]
Assessing genetic variants can help identify men with increased risk of prostate cancer

Assessing genetic variants can help identify men with increased risk of prostate cancer

Scientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease. [More]
Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. [More]
BGI-VPC Joint Research Laboratory to apply genome research to develop new cancer therapies

BGI-VPC Joint Research Laboratory to apply genome research to develop new cancer therapies

BGI, the world’s largest genomics organization, based in China, and The Vancouver Prostate Centre, a global leader in translational research in cancer, today announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including personalized oncology. [More]
Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at The University of Texas MD Anderson Cancer Center. [More]
New class of compounds protect brain cells from traumatic brain injury

New class of compounds protect brain cells from traumatic brain injury

A new class of compounds has now been shown to protect brain cells from the type of damage caused by blast-mediated traumatic brain injury (TBI). [More]
AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

The ovarian cancer market is highly active with several promising candidates having reached the late stages of development. Three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in mutated [BRCA-deficient] cancer cells, have been identified by Datamonitor Healthcare as front runners. [More]
Scientists crack genetic code of liver fluke parasite

Scientists crack genetic code of liver fluke parasite

Singapore-An international team of scientists from Singapore, Thailand, China and Australia has cracked the genetic code of the liver fluke parasite, Opisthorchis viverrini, using a unique DNA analysis technique developed at A*STAR's Genome Institute of Singapore (GIS). [More]
Professor receives award for development of anti-angiogenic therapy for retinal disease

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal. [More]
MRI and PET techniques can help monitor response of bone metastases to treatment

MRI and PET techniques can help monitor response of bone metastases to treatment

Imaging technologies are very useful in evaluating a patient's response to cancer treatment, and this can be done quite effectively for most tumors using RECIST, Response Evaluation Criteria in Solid Tumors. [More]
Merck's Keytruda gets FDA approval for treatment of malignant melanoma

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma. [More]
Dell, Terascala and TGen to install genomic data management solution at NCI

Dell, Terascala and TGen to install genomic data management solution at NCI

Dell, Terascala and the Translational Genomics Research Institute are installing state-of-the-art computing and programing specialized for human genome investigations at the National Cancer Institute. [More]
UW Carbone Cancer Center treats patients with MRIdian MRI-guided radiation therapy system

UW Carbone Cancer Center treats patients with MRIdian MRI-guided radiation therapy system

The MRIdian (me-rid-i-an) system from ViewRay, a privately held medical device company, is now being used to treat patients at the University of Wisconsin Carbone Cancer Center in Madison, Wisconsin, the second clinical group in the world to treat patients with MRI-guided radiation therapy. [More]
RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a study published in the September 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). [More]
African American women are 55% less likely to receive breast reconstruction after mastectomy

African American women are 55% less likely to receive breast reconstruction after mastectomy

Dartmouth researchers have found that African American women are 55 percent less likely to receive breast reconstruction after mastectomy regardless of where they received their care. [More]

Kinex Pharmaceuticals acquires QuaDPharma

Kinex Pharmaceuticals Inc. today announced that it has completed the acquisition of QuaDPharma, LLC., a Western New York based privately-held company specializing in pharmaceutical manufacturing, analytical and support services to the pharmaceutical and biotech industries. Financial terms of the transaction were not disclosed. [More]